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Introduction Patients affected by von Hippel-Lindau (VHL) disease experience an increased risk for bi-
lateral, synchronous, and metachronous renal cell carcinoma (RCC). Oncologic and functional outcomes 
are the main goals in the management of renal masses. We present our protocol for patients with VHL 
disease-associated RCC alongside functional and oncologic results observed in our series.
Material and methods We performed a retrospective analysis of our clinical database of patients with 
VHL disease-associated RCC referred to our department between June 2005 and December 2017.  
We offer surveillance for lesions <2 cm and active management with radiofrequency ablation (RFA)  
for lesions 2–3 cm, and nephron-sparing surgery (NSS), RFA or embolization techniques for lesions  
>3 cm or growth rate >1 cm/year.
Results Our series comprises 14 patients, of whom 13 had undergone at least one invasive procedure 
for RCC, mean age at first intervention was 27 years (range 18–60). Overall, 30 interventions were 
performed in 21 kidneys: four radical nephrectomies, 13 RFAs, 12 NSSs, and one embolization. During 
follow-up (median time: 41 months, range: 6–149), eight patients (57%) presented with new lesions 
that required treatment, with a mean time between treatments of 32 ±18.5 months. No metastatic 
progression or need for dialysis was recorded; the success rate for RFA was 85%.
Conclusions Management of VHL kidney disease by NSS is the standard of care with a cut-off at 3 cm, 
ablative procedures should be offered to lesions ranging 2–3 cm in size. Follow-up should be done 
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clude retinal angiomas, central nervous system he-
mangioblastomas, pheochromocytomas, pancreatic 
cystic lesions, neuroendocrine tumors, and cystad-
enomas of the epidermis, broad ligament and endo-
lymphatic sac [1, 2, 5].
RCCs in VHL patients are characterized by their 
multiplicity, bilaterality, and predominantly clear 
cell histology. They present with an age-dependent 
frequency, ranging from 25% up to 70%, with a mean 
age at diagnosis of 40 years of age [1, 2]. RCCs are 
the leading cause of death in patients with VHL, and 
INTRODUCTION
Von Hippel-Lindau (VHL) disease is the most com-
mon hereditary renal cell carcinoma (RCC) cancer 
syndrome, presenting in 1 in 36,000 live births [1]. 
It is an autosomal dominant, highly penetrant inher-
ited disorder caused by germline mutations in the 
VHL gene. VHL patients are at high risk of early and 
multiple clear cell RCC; approximately two-thirds 
will present multiple renal cysts and RCC during 
their lifetimes [1–4]. Extrarenal manifestations in-
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and accepted a percutaneous RFA or SE in their out-
patient clinic. Both the urologist and interventional 
radiologist provided an in-depth discussion of the 
pros and cons of each treatment modality, consider-
ing the size and location of the tumors selected for 
treatment. Controversial lesions are discussed at an 
oncologic multi-disciplinary meeting involving the 
interventional radiology and urology departments, 
which are held every 2 to 4 weeks. Follow-up after 
treatment includes magnetic resonance imaging 
(MRI) or computed tomography (CT) imaging of the 
abdomen at three months after surgery. If treatment 
is considered successful, an MRI is performed every 
six months thereafter. 
Variables and patient data were recorded in our 
clinical VHL database. Patient demographics in-
cluded: age, gender, confirmation of diagnosis with 
a genetic study, relatives affected, organs affected by 
VHL, Charlson comorbidity index, and renal status 
[serum creatinine and modification of diet in renal 
disease estimated glomerular filtration rate (eGFR)]. 
Therapeutic procedures recorded included: radi-
cal nephrectomy (RN), NSS, RFA, and SE. For each 
procedure, we recorded preoperative imaging char-
acteristics, baseline renal function status, procedure 
outcomes, and results (number, size, and anatomo-
pathological diagnosis including Fuhrman grade) 
and complications, according to the Clavien-Dindo 
classification. At the last follow-up visit, we recorded 
imaging results, oncologic, and renal function status. 
Time to disease progression was estimated as the 
time between procedures in every patient. Statistical 
analysis was performed using SPSS Statistics (V20; 
IBM Corp. Armonk, NY, USA).
RESULTS
From June 2005 to December 2017, 14 patients were 
referred to our VHL-RCC unit and consequently en-
rolled in our database. Three patients (22%) were 
women, and 11 (78%) men, the median age at diag-
nosis was 28 years old (range 18–60), and median 
age at the time of first intervention was 27 years 
(range 18–60), all of them having extrarenal mani-
festations. Demographic and perioperative data are 
summarized in  Table 1. Thirteen patients under-
went one or more procedures performed for RCC 
at our center, and one remains treatment naïve on 
active surveillance. Median follow-up in our series 
was 41 months (range 6–149).
Thirty procedures were performed overall in 21 kid-
neys, most commonly performed procedures were: 
13 RFAs and 12 NSSs (four open and eight laparo-
scopic), followed by four laparoscopic RNs and one 
SE. Before being referred to our department, four 
median overall survival in these patients is around 
50 years [1, 2]. The most important risk factors for 
decreased life expectancy in VHL patients are the 
high prevalence of RCC and their high recurrence 
rate [1, 2, 5].
Treatment decisions for RCCs in VHL depend 
on both the tumor size and growth kinetics of each 
lesion, as these parameters determine the risk 
of metastatic disease [6]. Nephron-sparing surgery 
(NSS) is currently the standard therapy for VHL-
associated RCC and should be performed whenever 
technically feasible, mainly for lesions measuring   
≥3 cm [7]. Percutaneous approaches for ablative tech-
niques such as cryoablation, radiofrequency ablation 
(RFA), and microwave ablation (MWA) should be 
considered for tumors measuring 2–3 cm in diameter 
distant from vessels or bowel structures [8]. Consid-
ering that these patients will have a large number 
of microscopic RCCs and abundant cysts, the balance 
between the number of surgeries for oncologic con-
trol and renal function preservation remains vital 
in the management of VHL kidney disease. We here-
in report our protocol for the management of VHL 
disease associated RCC, and our cohort of patients 
managed with invasive procedures. 
MATERIAL AND METHODS
We performed a retrospective analysis of a pro-
spectively collected database of patients with VHL 
disease treated for renal masses at our institution 
between June 2005 and December 2017. Our hospi-
tal is a referral center for the management of RCC 
in VHL disease with minimally invasive approaches, 
endorsed by the Spanish Alliance for Families with 
VHL disease. 
Patients were initially seen in the urology outpa-
tient clinic and a comprehensive consultation was 
provided covering the various treatment options 
available according to our protocols. We offer stan-
dardized management, with active surveillance 
for lesions <2 cm, which consists of urologic evalu-
ation and imaging every 3 to 6 months. Treatment 
is offered for lesions ≥2 cm or those with a growth 
rate of ≥1 cm/year. NSS (open or laparoscopic) is the 
preferred treatment modality for lesions ≥3 cm. RFA 
or MWA (percutaneous or laparoscopic) or percuta-
neous selective embolization (SE) are the preferred 
treatments for lesions measuring between 2 to 3 cm. 
Percutaneous ablative techniques (RFA and MWA) 
are not proposed for lesions that cannot be easily 
reached by the probe (anterior lesions), or located 
in close contact with adjacent structures (major ves-
sels or intraabdominal organs). The interventional 
radiologist would then see patients who were advised 
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patients had undergone ipsilateral RNs, managed 
initially as sporadic RCC at their local institutions 
(mean diameter of lesions: 90 mm, ±0.8). Patient 
and tumor characteristics stratified by treatment 
modality are summarized in Table 2.
At our department, the first treatment in every pa-
tient was decided upon specific localization of the 
tumor and its size. The median number of interven-
tions per patient was three (range 1–5). Procedures 
for the appearance of a new solid lesion (distant from 
the previously treated tumoral bed or contralateral) 
during follow-up were required in eight patients 
(57%) during a mean time (time from procedure 
to procedure) of 32 ±18.5 months (range 16–68). Re-
garding interventions for a new lesion during follow-
up, these were managed based on location, size, and 
previous treatment received; NSS was the most fre-
quently performed procedure (n = 5, 38%), followed 
by RFA (n = 4, 31%). Among the four patients re-
ferred to our institution with a single kidney, they 
required between one and 4 nephron-sparing proce-
dures each (3 NSS, 6 RFA, and 1 SE). Pathologic tu-
mor staging and Fuhrman’s tumor grade could only 
be determined in patients treated with either radi-
cal nephrectomy (RN) or NSS, and all cases showed 
clear cell carcinoma (Table 2). 
Failure to eradicate targeted lesions was observed in 
two patients, two times after RFA, and in one case 
after SE (success rate of FRA in our series: 85%). 
Both patients received a final successful treatment 
with NSS. 
No medical or surgical complications such as urinary 
tract infection, development of hematomas, wound 
Table 1. Demographic and perioperative data (n = 14)
Median age at diagnosis, years (range) 27 (18–60)
Male / female, n (%) 3 (22) / 11 (78)
Genetic study, n (%) 7 (50)
First-grade relative affected, n (%) 9 (64)
Extrarenal manifestations, n (%) 14 (100)
Cerebellar hemangioblastoma, n (%) 11 (79)
Pancreatic cysts, n (%) 9 (64)
Retinal angioma, n (%) 6 (43)
Pheochromocytoma, n (%) 2 (14)
Kidney solid lesions: unilateral / bilateral, n (%) 5 (36) / 9 (64)
Benign kidney lesions (Bosniak I), n (%) 11 (78)
Median BMI, kg/m2 (IQR) 23 (18–28)
Median Charlson score (Range) 2 (0–4)
Patients that had only one intervention for kidney 
tumors (%) 5 (36)
Patients with multiple interventions for kidney 
tumors (%) 8 (57)
Treatment naïve patients (%) 1 (7)










BMI – body mass index; IQR – interquartile range; eGFR – estimated glomerular 
filtration rate; SD standard deviation; CKD-EPI – Chronic Kidney Disease Epidemiology 
Collaboration
Table 2. Invasive procedures performed in our series of patients with von Hippel-Lindau disease associated renal cell carcinoma 









Number of procedures, n 4 12 13 1
Number of patients*, n /total 4/13 10/13 8/13 1/13
Mean diameter of lesions, mm (±SD) 90 (±0.8) 31.6 (±8.3) 2.7 (±8.8) 26








Not assessed Not assessed










Not assessed Not assessed
Transfusion rate, % 0% 0% 0% 0%
Complications (Clavien-Dindo classification) 0 0 IIIb 0
SD – standard deviation
*Considering that patients have received more than one treatment option at a different time (except for radical nephrectomy)
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[7, 16, 17]. The decision when to excise RCCs 
is mainly made on the basis of the tumor size and 
the growth kinetics of every lesion as both of these 
parameters determine the risk of metastatic disease 
[1, 17]. In a retrospective study described by Duffey 
et al. [17], tumor size was significantly associated 
with the likelihood of metastatic spread. In 108 re-
viewed patients, they used the 3 cm threshold to rec-
ommend surgical treatment, observing the absence 
of metastatic progression during a median follow-up 
of 41 months (range 0–244).  Currently, the accepted 
cut-off diameter for surgical resections is considered 
3 cm [1]. If we follow this recommendation, expect-
ed disease progression survival is achieved at a rate 
of 76% at 5 years and 20% at 8 years [13, 14, 15, 17]. 
In this setting, organ-sparing strategies such as NSS 
should be performed whenever technically feasible, 
leaving RN only for cases of functional organ loss, 
or when the risks of preserving the remaining paren-
chyma outweigh the benefits. 
In our series, 76% of patients underwent a NSS 
(12 procedures in 11 kidneys), the mean diameter 
of lesions was 31.6 ±8.3 mm. From all 12 NSS, 
8 cases were successfully performed laparoscopically, 
and the remaining 4 were performed using an open 
approach (3 patients had multiple tumors, and 1 had 
an ipsilateral previous laparoscopic NSS). The four 
patients in our series that underwent a RN before 
the referral to our center presented cT2 lesions in all 
cases (mean diameter of 90 mm), not being suitable 
for a NSS. 
Thirteen percutaneous ablative procedures (RFA) 
were performed in our cohort, all done under 
CT-guidance. The mean diameter of solid lesions 
treated by RFA was 25.7 ±8.8 mm. We observed 
a success rate of RFA for the treatment of renal tu-
mors of 85%, with only two patients that required re-
treatment. In one patient, the recurrence after RFA 
(32 mm solid lesion) was treated successfully with 
NSS after six months of the initial procedure. The 
second patient, who had a solitary kidney, received 
a SE after six months of the FRA for a 24 mm lesion. 
This same lesion needed a new intervention, this 
time with a NSS 15 months after the SE (surgery 
was planned for the formerly described lesion and 
a new one of 25 mm). This overall oncologic techni-
cal success rate is similar to the currently published 
data, with reported success rates of RFA from 90% 
to 100% [18–21]. During the last years, minimally 
invasive percutaneous techniques have gained in-
creased relevance and have shown their efficacy 
in the treatment of RCC; these include CT-guided 
cryoablation, RFA, and MWA [8, 18, 22]. As a clinical 
principle, these techniques should be considered for 
tumors measuring 2–3 cm in diameter, which are not 
infection, nor urinary fistula were recorded, and the 
transfusion rate was 0%. Only one high grade (IIIb) 
complication was reported out of 30 interventions 
(3% complication rate): a colonic thermal injury dur-
ing a RFA session that required a Hartmann proce-
dure and deferred bowel reconstruction.
At the first visit, all patients presented with ade-
quate renal function, with a mean estimated glomer-
ular filtration rate (eGFR) of ≥90 ml/minute/1.73 m2 
(Table 1), without associated nephropathy. Despite 
multiple interventions, adequate renal function was 
maintained in all patients at the last follow-up.  Over-
all, mean serum creatinine at last visit was 1.0 mg/dl 
(±0.7) with a mean eGFR of 74.2 ml/minute/1.73 m2 
(±25.1). As expected, patients with a solitary kidney 
developed a worse renal function outcome, of whom 
50% developed stage 3 chronic kidney disease (eGFR 
less than 60 ml/minute/1.73 m2) (Table 2). No need 
for renal replacement therapy was observed at any 
time in our series.
DISCUSSION
A small proportion of RCCs are heritable (2–4%), 
characterized by a younger age at presentation, and 
are mostly multifocal, bilateral, and recur over time 
[9]. At least 12 different inherited renal cancer syn-
dromes have been described, from which VHL is the 
most common and widely investigated, recognized 
as the best-defined RCC susceptibility syndrome [2]. 
Approximately two-thirds of VHL patients present 
renal cysts and RCC, which tend to be bilateral in at 
least 75% of cases [1, 2, 10]. The most critical risk 
factor for decreased life expectancy in VHL patients 
is the high prevalence of RCC. The lifelong develop-
ment of RCC in these patients will eventually re-
sult in chronic kidney disease after repeated surgi-
cal treatments, with the resultant higher incidence 
of cardiovascular events and death. Thus, the aver-
age survival in this population is around 50 years 
of age [1, 11, 12]. 
Our series comprises 14 patients already diagnosed 
with VHL disease who were referred to our unit for 
the treatment and follow-up of small renal masses, 
of whom 13 received invasive treatments. The most 
recently updated series describing the management 
of kidney tumors in VHL patients range from 14 
to 44 cases [13, 14, 15].
The management of renal masses in VHL patients 
is considered a technical challenge. Clinical guide-
lines do not provide definitive recommendations 
for the therapeutic decisions regarding small-size 
RCCs because of the absence of high volume clini-
cal trials and the absence of patients with hereditary 
renal cancer syndromes in the published literature 
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not significantly reduced after percutaneous tech-
niques for sporadic RCC [18, 22, 29, 30]. Wah et al. 
reported a 3.1% loss of the eGFR after RFAs when 
comparing the eGFR before treatment [18]. We ob-
served a decrease of >25% of eGFR at last visit in 
only one patient, which had a solitary kidney and 
had undergone 2 RFAs, one SE, and one partial ne-
phrectomy, not requiring renal replacement therapy 
at last follow-up. 
After successful treatments, we observed the appear-
ance of new lesions (distant to the operated kidney 
surgical bed) requiring active treatment in 8 patients 
(57%) within a mean time of 32 ±18.5 months (range 
16–68). In a relevant published series by Ploussard 
et al. [13], in 21 VHL patients with RCC, 8 (38%) de-
veloped new lesions, at a median time of 43 months 
(range 10–115). Our shorter time to disease progres-
sion can be explained by the use of percutaneous ab-
lative techniques (RFA) to treat smaller renal lesions 
in our patients. If we only take into account patients 
who underwent a repeated NSS for a new renal le-
sion (5 cases, 36%), like Ploussard et al., the median 
time to progression was similar: 41 months (range 
5–64) [13].
In the present series, we outline that all patients re-
ferred to our center, whether their status was treat-
ment naïve or with a solitary kidney after an initial 
RN, were treated successfully according to our in-
ternal protocol. We managed to preserve renal func-
tion in all cases, and no development of metastases 
or death was documented during follow-up.  
CONCLUSIONS
VHL is a rare hereditary disease that can develop 
bilateral synchronous and metachronous RCCs. 
Management of VHL kidney disease by NSS is the 
standard of care with a cut-off at 3 cm, while abla-
tive procedures should be offered to lesions rang-
ing 2–3 cm in size distant from vessels or bowel 
structures. Minimally invasive procedures like 
NSS or percutaneous RFA offer good oncologic re-
sults with an acceptable complication rate. Patients 
should be closely followed up and managed in refer-
ral centers, which can offer all treatment options 
to preserve renal function and control oncologic 
progression. 
CONfLICTS Of INTEREST
The authors declare no conflicts of interest.
fUNDING 
This research was funded by Madrid Regional Government Re-
search Grant [S2010/BMD-2326 IMMUNOTHERCAN-CM (B2017/
BMD-3733)/FEDER].
close to vessels or bowel structures. Tumors larger 
than 3 cm are not easily treated with RFA because 
of the probability of requiring multiple RFA sessions 
for complete ablation and the uncertainty of obtain-
ing complete destruction of the tumor [8, 15, 21, 23]. 
Some technical limitations were described at the be-
ginning of the series in patients who were not candi-
dates for surgical resection, but later on, researchers 
have shown promising results of the procedures, with 
low complication rates [8, 23–25]. The complication 
rate of percutaneous ablative procedures for treating 
RCCs is 0–8% in patients with VHL disease [8, 21]. 
These include bowel perforation, ureteral strictures, 
uncontrolled bleeding, and residual or recurrent 
cancers [26]. We observed only one major complica-
tion in our series (7%), a thermal bowel injury, which 
corresponds to the most frequently reported compli-
cation described in the current literature [8, 18, 25]. 
Bowel injury is also the most severe complication be-
cause it can eventually result in perforation, abscess 
formation, and sepsis [26]. The minor complication 
rate following ablative procedures is relatively high, 
reaching 58–66%, and includes hematuria, hema-
tomas, pneumothorax, and segmental renal infarc-
tion [8, 22]. In the case of our patient that suffered 
a colon injury, bowel structures were not considered 
at a risky distance from the tumor, understanding 
that the procedure was well indicated in the first 
case, and the development of this complication was 
not expected. 
Considering the high frequency of multiple neo-
plastic foci, and the young age at diagnosis of RCC 
in VHL patients, subsequent surgeries and interven-
tions will be required in each kidney during their 
lifetime. The main therapeutic goal to manage RCCs 
in patients with VHL disease is to remove as many 
RCCs as possible while preserving renal function. 
Patients will undergo NSS for visible lesions with 
the general understanding that microscopic cancer 
cells will probably remain in non-detected foci, and 
will develop tumors in the future [27]. Therefore, 
patients and physicians should always have in mind 
that the number of possible interventions in one kid-
ney may be limited, and the need for surgery should 
be considered carefully. The two main targets for 
the urologist in every patient with this disorder are 
to avoid metastatic disease and delay the need for 
dialysis. We must keep in mind that quality of life in 
these patients has been shown to correlate inversely 
with the number of operations a patient has under-
gone on the kidneys and central nervous system [28]. 
Although a gradual reduction of renal function is un-
avoidable following either NSS or RFA due to paren-
chymal loss [23, 25], recently published studies have 
reported that renal preservation can be achieved and 
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